1. Bui, AL, Horwich, TB, Fonarow, GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30.
Google Scholar | Crossref | Medline | ISI2. Van Deursen, V.M, Urso, R, Laroche, C, et al. Co-morbidities in patients with heart failure: An analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014; 16: 103–111.
Google Scholar | Crossref | Medline3. Ather, S, Chan, W, Bozkurt, B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998–1005.
Google Scholar | Crossref | Medline | ISI4. Eknoyan, G, Lameire, N, Eckardt, K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3: 5–14.
Google Scholar | ISI5. Matsushita, K, van der Velde, M, Astor, BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010; 375: 2073–2081.
Google Scholar | Crossref | Medline | ISI6. Segall, L, Nistor, I and, Covic, A. Heart failure in patients with chronic kidney disease: A systematic integrative review. Biomed Res Int 2014; 937398.
Google Scholar7. Sud, M, Tangri, N, Pintilie, M, et al. Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation 2014; 130: 458–465.
Google Scholar | Crossref | Medline | ISI8. Gansevoort, RT, Correa-Rotter, R, Hemmelgarn, BR, et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339–352.
Google Scholar | Crossref | Medline | ISI9. Kottgen, A, Russell, SD, Loehr, LR, et al. Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007; 18: 1307–1315.
Google Scholar | Crossref | Medline10. Collins, AJ, Foley, RN, Gilbertson, DT, et al. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl 2015; 5: 2–7.
Google Scholar | Crossref11. Damman, K, Valente, MA, Voors, AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014; 35: 455–469.
Google Scholar | Crossref | Medline | ISI12. Roger, VL, Go, AS, Lloyd-Jones, DM, et al. Heart disease and stroke statistics—2011 update: A report from the American Heart Association. Circulation 2011; 123: e18–e209.
Google Scholar | Crossref | Medline | ISI13. Ahmed, A, Rich, MW, Sanders, PW, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: A propensity matched study. Am J Cardiol 2007; 99: 393–398.
Google Scholar | Crossref | Medline | ISI14. Smith, DH, Thorp, ML, Gurwitz, JH, et al. Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: The Cardiovascular Research Network PRESERVE Study. Circ Cardiovasc Qual Outcomes 2013; 6: 333–342.
Google Scholar | Crossref | Medline15. Hillege, HL, Nitsch, D, Pfeffer, MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671–678.
Google Scholar | Crossref | Medline | ISI16. Harjola, VP, Mullens, W, Banaszewski, M, et al. Organ dysfunction, injury and failure in acute heart failure: From pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2017; 19: 821–836.
Google Scholar | Crossref | Medline17. Damman, K, Testani, JM. The kidney in heart failure: An update. Eur Heart J 2015; 36: 1437–1444.
Google Scholar | Crossref | Medline | ISI18. Damman, K, Gori, M, Claggett, B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018; 6: 489–498.
Google Scholar | Crossref | Medline19. Mullens, W, Martens, P. Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure. JACC Heart Fail 2014; 6: 499–502.
Google Scholar20. Brunner-La Rocca, HP, Knackstedt, C, Eurlings, L, et al.; TIME-CHF investigators . Impact of worsening renal function related to medication in heart failure. Eur J Heart Fail 2015; 17: 159–168.
Google Scholar | Crossref | Medline21. Gilstrap, LG, Stevenson, LW, Small, R, et al. Reasons for guideline nonadherence at heart failure discharge. J Am Heart Assoc 2018; 7: e008789.
Google Scholar | Crossref | Medline22. Schefold, JC, Filippatos, G, Hasenfuss, G, et al. Heart failure and kidney dysfunction: Epidemiology, mechanisms and management. Nat Rev Nephrol 2016; 12: 610.
Google Scholar | Crossref | Medline | ISI23. Tsuruya, K and, Eriguchi, M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens 2015; 24: 154–162.
Google Scholar | Crossref | Medline24. Graziani, G, Pini, D, Oldani, S, et al. Renal dysfunction in acute congestive heart failure: A common problem for cardiologists and nephrologists. Heart Fail Rev 2014; 19: 699–708.
Google Scholar | Crossref | Medline | ISI25. Gladden, JD, Chaanine, AH and, Redfield, MM. Heart failure with preserved ejection fraction. Ann Rev Med 2018; 69: 65–79.
Google Scholar | Crossref | Medline26. Mullens, W, Damman, K, Testani, JM, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22: 584–603.
Google Scholar27. Gladden, JD, Chaanine, AH and, Redfield, MM. Heart failure with preserved ejection fraction. Ann Rev Med 2018; 69: 65–79.
Google Scholar | Crossref | Medline28. Fröhlich, H, Nelges, C, Täger, T, et al. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease. Am Heart J 2016; 178, 28–36.
Google Scholar | Crossref | Medline29. Ahmed, A, Fonarow, GC, Zhang, Y, et al. Renin–angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 2012; 125: 399–410.
Google Scholar | Crossref | Medline30. Zannad, F, McMurray, JJ, Krum, H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
Google Scholar | Crossref | Medline | ISI31. Rossignol, P, Cleland, JG, Bhandari, S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012; 125: 271–279.
Google Scholar | Crossref | Medline | ISI32. Damman, K, Gori, M, Claggett, B, et al. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail 2018; 6: 489–498.
Google Scholar | Crossref | Medline33. Solomon, SD, Zile, M, Pieske, B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387–1395.
Google Scholar | Crossref | Medline | ISI34. Badve, SV, Roberts, MA, Hawley, CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: A systematic review and meta-analysis. J Am Coll Cardiol 2011; 58: 1152–1161.
Google Scholar | Crossref | Medline | ISI35. Ghali, JK, Wikstrand, J, van Veldhuisen, DJ, et al. The influence of renal function on clinical outcome and response to β-blockade in systolic heart failure: Insights from metoprolol CR/XL randomized intervention trial in chronic HF (MERIT-HF). J Card Fail 2009; 15: 310–318.
Google Scholar | Crossref | Medline36. Cohen-Solal, A, Kotecha, D, van Veldhuisen, DJ, et al.; SENIORS Investigators . Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: Insights from the SENIORS trial. Eur J Heart Fail 2009; 11: 872–880.
Google Scholar | Crossref | Medline | ISI37. Castagno, D, Jhund, PS, McMurray, JJ, et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: An analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. Eur J Heart Fail 2010; 12: 607–616.
Google Scholar | Crossref | Medline38. Prattichizzo, F, La Sala, L, Rydén, L, et al. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. Eur J Prev Cardiol 2019; 26:73–80.
Google Scholar | SAGE Journals | ISI39. McMurray, J., Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995–2008.
Google Scholar | Crossref | Medline40. Levin, A, Stevens, PE, Bilous, RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1–150.
Google Scholar41. Nimmo, AJ, Than, N, Orchard, CH, et al. The effect of acidosis on beta-adrenergic receptors in ferret cardiac muscle. Exp Physiol 1993; 78: 95–103.
Google Scholar | Crossref | Medline42. Kirkman, DL, Muth, BJ, Stock, JM, et al. Cardiopulmonary exercise testing reveals subclinical abnormalities in chronic kidney disease. Eur J Prev Cardiol 2018; 25: 1717–1724.
Google Scholar | SAGE Journals | ISI43. Scrutinio, D, Agostoni, P, Gesualdo, L, et al. Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction. Circulation J 2015; 79: 583–591.
Google Scholar | Crossref | Medline44. McCullough, PA, Franklin, BA, Leifer, E, et al.; HF-ACTION Investigators . Impact of reduced kidney function on cardiopulmonary fitness in patients with systolic heart failure. Am J Nephrol 2010; 32: 226–233.
Google Scholar | Crossref | Medline45. Van Laethem, C, Bartunek, J, Goethals, M, et al. Chronic kidney disease is associated with decreased exercise capacity and impaired ventilatory efficiency in heart transplantation patients. J Heart Lung Transpl 2010; 28: 446–52.
Google Scholar | Crossref46. Floras, JS. Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model. J Am Coll Cardiol 2009; 54: 375–385.
Google Scholar | Crossref | Medline | ISI47. Parati, G, Esler, M. The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33: 1058–1066.
Google Scholar | Crossref | Medline | ISI48. Lymperopoulos, A, Rengo, G, Koch, WJ. Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ Res 2013; 113: 739–753.